Arcellx, Inc.
ACLX
Classement en actions
#2771
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Prix de l'action
$115.07
Dernière synchronisation: 2026-05-15
Capitalisation boursière
$6.73B
Changement (1 jour)
0.00%
Changement (1 an)
34.40%
Pays
US
Échange Arcellx, Inc. (ACLX)
Catégorie
Healthcare
Revenus pour Arcellx, Inc. (ACLX)
Revenus en Dec 2025 TTM : $22.29M
Selon les derniers rapports financiers de Arcellx, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $22.29M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $110.32M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de 0.00. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Arcellx, Inc. de 2018 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $22.29M | -79.35% |
| 2024 | $107.94M | -2.16% |
| 2023 | $110.32M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 56,546.77% |
US
|
|
| $2.23B | 9,897.31% |
US
|
|
| $15.74B | 70,546.72% |
AU
|
|
| $6.02B | 26,918.25% |
NL
|
|
| - | - |
CH
|
